噻唑烷二酮类药物治疗会降低2型糖尿病男性患者的骨密度。 - Suppr

Suppr

超能文献

Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.

作者信息

Yaturu Subhashini, Bryant Barbara, Jain Sushil K

机构信息

Department of Endocrinology, Overton Brooks VA Medical Center, Shreveport, Louisiana 71101-4295, USA.

出版信息

Diabetes Care. 2007 Jun;30(6):1574-6. doi: 10.2337/dc06-2606. Epub 2007 Mar 15.

DOI:10.2337/dc06-2606

PMID:17363747

Abstract

摘要

相似文献

Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.

Diabetes Care. 2007 Jun;30(6):1574-6. doi: 10.2337/dc06-2606. Epub 2007 Mar 15.

Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance?

Diabetes Care. 2007 Jun;30(6):1670-1. doi: 10.2337/dc07-0554.

[Thiazolidinediones and skeletal health].

Rev Med Suisse. 2009 Jun 10;5(207):1309-10, 1312-3.

Thiazolidinedione use and the risk of fractures.

CMAJ. 2009 Apr 14;180(8):841. doi: 10.1503/cmaj.1090005.

Thiazolidinediones: antidiabetic agents with effects on bone.

Joint Bone Spine. 2009 May;76(3):221-3. doi: 10.1016/j.jbspin.2009.01.005. Epub 2009 Apr 11.

Thiazolidinedione use and the risk of fractures.

CMAJ. 2009 Apr 14;180(8):841-2; author reply 842-3. doi: 10.1503/cmaj.1090003.

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.

Diabetes Obes Metab. 2010 Aug;12(8):716-21. doi: 10.1111/j.1463-1326.2010.01225.x.

Type 2 diabetes, thiazolidinediones: bad to the bone?

J Clin Endocrinol Metab. 2006 Sep;91(9):3276-8. doi: 10.1210/jc.2006-1235.

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

CMAJ. 2009 Jan 6;180(1):32-9. doi: 10.1503/cmaj.080486. Epub 2008 Dec 10.

Thiazolidinediones: do harms outweigh benefits?

CMAJ. 2009 Jan 6;180(1):16-7. doi: 10.1503/cmaj.081713. Epub 2008 Dec 10.

引用本文的文献

Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes.

Diabetes Metab Syndr Obes. 2023 Dec 27;16:4205-4214. doi: 10.2147/DMSO.S439479. eCollection 2023.

The Role of PPARs in Breast Cancer.

Cells. 2022 Dec 28;12(1):130. doi: 10.3390/cells12010130.

A narrative review of diabetic bone disease: Characteristics, pathogenesis, and treatment.

Front Endocrinol (Lausanne). 2022 Dec 14;13:1052592. doi: 10.3389/fendo.2022.1052592. eCollection 2022.

Secondary Osteoporosis and Metabolic Bone Diseases.

J Clin Med. 2022 Apr 24;11(9):2382. doi: 10.3390/jcm11092382.

Molecular Modulation of Osteoblasts and Osteoclasts in Type 2 Diabetes.

J Diabetes Res. 2018 Nov 4;2018:6354787. doi: 10.1155/2018/6354787. eCollection 2018.

Diabetes pharmacotherapy and effects on the musculoskeletal system.

Diabetes Metab Res Rev. 2019 Feb;35(2):e3100. doi: 10.1002/dmrr.3100. Epub 2018 Dec 20.

Marrow Adipose Tissue: Its Origin, Function, and Regulation in Bone Remodeling and Regeneration.

Stem Cells Int. 2018 May 31;2018:7098456. doi: 10.1155/2018/7098456. eCollection 2018.

Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.

Br J Clin Pharmacol. 2018 Sep;84(9):2029-2039. doi: 10.1111/bcp.13636. Epub 2018 Jun 29.

The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus.

Intern Med. 2017;56(11):1301-1306. doi: 10.2169/internalmedicine.56.8096. Epub 2017 Jun 1.

Succinate and its G-protein-coupled receptor stimulates osteoclastogenesis.

Nat Commun. 2017 May 31;8:15621. doi: 10.1038/ncomms15621.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.

Diabetes Care. 2007 Jun;30(6):1574-6. doi: 10.2337/dc06-2606. Epub 2007 Mar 15.

Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance?

Diabetes Care. 2007 Jun;30(6):1670-1. doi: 10.2337/dc07-0554.

[Thiazolidinediones and skeletal health].

Rev Med Suisse. 2009 Jun 10;5(207):1309-10, 1312-3.

Thiazolidinedione use and the risk of fractures.

CMAJ. 2009 Apr 14;180(8):841. doi: 10.1503/cmaj.1090005.

Thiazolidinediones: antidiabetic agents with effects on bone.

Joint Bone Spine. 2009 May;76(3):221-3. doi: 10.1016/j.jbspin.2009.01.005. Epub 2009 Apr 11.

Thiazolidinedione use and the risk of fractures.

CMAJ. 2009 Apr 14;180(8):841-2; author reply 842-3. doi: 10.1503/cmaj.1090003.

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.

Diabetes Obes Metab. 2010 Aug;12(8):716-21. doi: 10.1111/j.1463-1326.2010.01225.x.

Type 2 diabetes, thiazolidinediones: bad to the bone?

J Clin Endocrinol Metab. 2006 Sep;91(9):3276-8. doi: 10.1210/jc.2006-1235.

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

CMAJ. 2009 Jan 6;180(1):32-9. doi: 10.1503/cmaj.080486. Epub 2008 Dec 10.

Thiazolidinediones: do harms outweigh benefits?

CMAJ. 2009 Jan 6;180(1):16-7. doi: 10.1503/cmaj.081713. Epub 2008 Dec 10.

引用本文的文献

Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes.

Diabetes Metab Syndr Obes. 2023 Dec 27;16:4205-4214. doi: 10.2147/DMSO.S439479. eCollection 2023.

The Role of PPARs in Breast Cancer.

Cells. 2022 Dec 28;12(1):130. doi: 10.3390/cells12010130.

A narrative review of diabetic bone disease: Characteristics, pathogenesis, and treatment.

Front Endocrinol (Lausanne). 2022 Dec 14;13:1052592. doi: 10.3389/fendo.2022.1052592. eCollection 2022.

Secondary Osteoporosis and Metabolic Bone Diseases.

J Clin Med. 2022 Apr 24;11(9):2382. doi: 10.3390/jcm11092382.

Molecular Modulation of Osteoblasts and Osteoclasts in Type 2 Diabetes.

J Diabetes Res. 2018 Nov 4;2018:6354787. doi: 10.1155/2018/6354787. eCollection 2018.

Diabetes pharmacotherapy and effects on the musculoskeletal system.

Diabetes Metab Res Rev. 2019 Feb;35(2):e3100. doi: 10.1002/dmrr.3100. Epub 2018 Dec 20.

Marrow Adipose Tissue: Its Origin, Function, and Regulation in Bone Remodeling and Regeneration.

Stem Cells Int. 2018 May 31;2018:7098456. doi: 10.1155/2018/7098456. eCollection 2018.

Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.

Br J Clin Pharmacol. 2018 Sep;84(9):2029-2039. doi: 10.1111/bcp.13636. Epub 2018 Jun 29.

The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus.

Intern Med. 2017;56(11):1301-1306. doi: 10.2169/internalmedicine.56.8096. Epub 2017 Jun 1.

Succinate and its G-protein-coupled receptor stimulates osteoclastogenesis.

Nat Commun. 2017 May 31;8:15621. doi: 10.1038/ncomms15621.